Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30997824 | 0.89 | HTR2C (0.77) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL1515134 | 0.89 | HTR2C (0.77) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL1515075 | 0.85 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| Methyl Alcohol SCHEMBL8097139 | 0.85 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL7844832 | 0.85 | HTR2C (0.72) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| Ammonia Solution, Strong SCHEMBL19664329 | 0.84 | HTR2C (0.70) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL2095198 | 0.84 | HTR2C (0.70) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL28695004 | 0.82 | HTR2C (0.68) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL3684647 | 0.81 | TP53 (0.50) | HTR2CDRD2ADRA1AHTR1AADRA1D | |
| SCHEMBL3316532 | 0.81 | HTR2C (0.66) | HTR2CDRD2ADRA1AHTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
| CN-1538956-A | Spiro compounds | ������ҩ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR2C 14/4885DRD2 172/4885ADRA1A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.